NCT03523273

Pilot Study of the Effect of Liraglutide 3.0 mg on Weight Loss and Gastric Functions in Obesity

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 136 (actual)
• Sponsor: Michael Camilleri, MD · Academic / Other
• Sex: All
• Age: 18 Years – 65 Years
• Healthy volunteers: Accepted

Summary

This study is being done to assess the stomach emptying effect of a maximum dose of 3 mg Liraglutide compared to placebo in subjects who are overweight or obese. Liraglutide is a medication approved by the Food and Drug Administration (FDA) for routine clinical use.

Conditions

• Obesity

Interventions

Type	Name	Description
DRUG	Liraglutide	Initiate at 0.6mg S.C. daily for 1 week; subjects will return to the Clinical Research Unit (CRU) each week until an increase by 0.6mg/day in weekly intervals to a dose of 3.0 mg/day is achieved (\~4 weeks). Once maintenance dose of 3.0 mg is achieved, subjects will return approximately every 4 weeks to obtain new supply of study medication.
DRUG	Placebo	Placebo administration will match the study drug.

Timeline

• Start date: 2017-11-29
• Primary completion: 2021-08-31
• Completion: 2021-08-31
• First posted: 2018-05-14
• Last updated: 2022-06-23
• Results posted: 2022-06-23

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated drug study